The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
MiR‐200c suppresses TGF‐β signaling and counteracts trastuzumab resistance and metastasis by targeting ZNF217 and ZEB1 in breast cancer
Open accessAbstract
Resistance to trastuzumab and concomitantly distal metastasis are leading causes of mortality in HER2‐positive breast cancers, the molecular basis of which remains largely unknown. Here, we generated trastuzumab‐resistant breast cancer cells with increased tumorigenicity and invasiveness compared with parental cells, and observed robust epithelial–mesenchymal transition (EMT) and consistently elevated TGF‐β signaling in these cells. MiR‐200c, which was the most significantly downregulated miRNA in trastuzumab‐resistant cells, restored trastuzumab sensitivity and suppressed invasion of breast cancer cells by concurrently targeting ZNF217, a transcriptional activator of TGF‐β, and ZEB1, a known mediator of TGF‐β signaling. Given the reported backward inhibition of miR‐200c by ZEB1, ZNF217 also exerts a feedback suppression of miR‐200c via TGF‐β/ZEB1 signaling. Restoration of miR‐200c, silencing of ZEB1 or ZNF217 or blockade of TGF‐β signaling increased trastuzumab sensitivity and suppressed invasiveness of breast cancer cells. Therefore, our study unraveled nested regulatory circuits of miR‐200c/ZEB1 and miR‐200c/ZNF217/TGF‐β/ZEB1 in synergistically promoting trastuzumab resistance and metastasis of breast cancer cells. These findings provide novel insights into the common role of EMT and related molecular machinery in mediating the malignant phenotypes of breast cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Massagué, J. (2008) · Cell · doi:10.1016/j.cell.2008.07.001 · Cited by 3,907
Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits
Polyak, K., & Weinberg, R. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2620 · Cited by 3,302
Park, S.-M., Gaur, A. B., Lengyel, E., & Peter, M. E. (2008) · Genes & Development · doi:10.1101/gad.1640608 · Cited by 2,272
MED12 Controls the Response to Multiple Cancer Drugs through Regulation of TGF-β Receptor Signaling
Huang, S., Hölzel, M., Knijnenburg, T., Schlicker, A., Roepman, P., McDermott, U., Garnett, M., Grernrum, W., Sun, C., Prahallad, A., et al. (2012) · Cell · doi:10.1016/j.cell.2012.10.035 · Cited by 430
Ulanet, D. B., Ludwig, D. L., Kahn, C. R., & Hanahan, D. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0914076107 · Cited by 235
Cited by
The role and mechanisms of action of microRNAs in cancer drug resistance
Si, W., Shen, J., Zheng, H., & Fan, W. (2019) · Clinical Epigenetics · doi:10.1186/s13148-018-0587-8 · Cited by 668
EMT‐associated microRNAs and their roles in cancer stemness and drug resistance
Pan, G., Liu, Y., Shang, L., Zhou, F., & Yang, S. (2021) · Cancer Communications · doi:10.1002/cac2.12138 · Cited by 362
LncRNA-ATB promotes trastuzumab resistance and invasion-metastasis cascade in breast cancer
Shi, S.-J., Wang, L.-J., Yu, B., Li, Y.-H., Jin, Y., & Bai, X.-Z. (2015) · Oncotarget · doi:10.18632/oncotarget.3457 · Cited by 316
van Staalduinen, J., Baker, D., ten Dijke, P., & van Dam, H. (2018) · Oncogene · doi:10.1038/s41388-018-0378-x · Cited by 158
Breast cancer: miRNAs monitoring chemoresistance and systemic therapy
Singh, S., Saini, H., Sharma, A., Gupta, S., Huddar, V. G., & Tripathi, R. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1155254 · Cited by 25
Metadata
- Authors
- Bai, W., Ye, X., Zhang, M., Zhu, H., Xi, W., Huang, X., Zhao, J., Gu, B., Zheng, G., Yang, A., & Jia, L.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2014-03-03
- Volume
- 135
- Issue
- 6
- Pages
- 1356-1368
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2149189351
- Cited by
- 178
- References
- 5
- FWCI
- 6.22
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.